In the era of personalized medicine, having noninvasive or minimally invasive methods to determine and follow longitudinally the status of kidney disease at the molecular level is essential. One such approach is through liquid biopsy that can be used to molecularly characterize the disease and monitor genetic, proteomic, and metabolomic changes over time using repeat sampling of biofluids.
221 Longwood Avenue
Boston, MA 02115
Annenberg Building Floor 21 Room 20
1468 Madison Ave
New York, NY 10029